|
Jul 2
|
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 1
|
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|
|
Jun 27
|
Incyte Stock Gets Relative Strength Rating Lift
|
|
Jun 27
|
Shell denies deal talks with BP, Micron reports Q3 beat: Morning Buzz
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
|
|
May 22
|
3 Reasons INCY is Risky and 1 Stock to Buy Instead
|
|
May 20
|
3 Mid-Cap Stocks with Questionable Fundamentals
|
|
May 15
|
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
|
|
May 14
|
Incyte Corporation (INCY): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying
|
|
May 13
|
INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance
|
|
Mar 1
|
Is Incyte Corporation (INCY) The Best Immunology Stock To Buy Now?
|
|
Feb 28
|
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
|
|
Feb 28
|
High Growth Tech Stocks to Watch in US Market February 2025
|
|
Feb 25
|
Incyte Corporation (INCY) Partners with Genesis AI to Accelerate Drug Discovery
|
|
Feb 17
|
3 US Stocks Estimated To Be 14.6% To 47.8% Below Intrinsic Value
|
|
Feb 11
|
Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Feb 11
|
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook
|
|
Jan 30
|
Exploring High Growth Tech Stocks In January 2025
|